Clinical development failure or delay
The pipeline is based on novel gene therapy and ophthalmic mechanisms with uncertain trial outcomes and timelines.
- Scope
- LCA5, BEST1, RHO, APX3330
- Materiality
- high
Opus Genetics, Inc.
Opus Genetics, Inc. is a U.S.-based clinical-stage biopharmaceutical company focused on gene therapies for inherited retinal diseases and other ophthalmic disorders. Its pipeline includes AAV-based gene therapy programs, a small-molecule ophthalmic candidate, and a licensed eye-drop product that generates royalty revenue through a partner.
−271,5 %
−349,3 %
+29,1 %
6.43
6.43
| % | |
|---|---|
| Gene therapy programs | 0% AAV-based therapies targeting inherited retinal disease mutations and other ophthalmic disorders. |
| Licensed ophthalmic product | 15% Phentolamine Ophthalmic Solution 0.75% marketed by a partner and generating royalties. |
| Small-molecule ophthalmology candidate | 0% APX3330, a Ref-1 inhibitor being developed for diabetic retinopathy. |
| License and collaboration revenue | 85% Milestones, reimbursements, and other non-product revenue from partners. |
Opus primarily serves patients with inherited retinal diseases and other serious eye disorders through its development...
- Rare disease patients and caregiversprimary
Patients with IRDs, LCA, bestrophinopathy, or retinitis pigmentosa who would receive approved gene therapies or ophthalmic treatments.
- Pharmaceutical and biotech partnersprimary
Licensees and collaborators that fund development, pay milestones, or commercialize partnered assets such as RYZUMVI®.
- Eye care specialistssecondary
Retina specialists and ophthalmologists who would diagnose, refer, and prescribe if pipeline assets are approved.
- Payers and health systemssecondary
Insurers and healthcare systems that would reimburse high-value ophthalmic therapies after approval.
Opus is headquartered in the United States and operates as a U.S. biopharmaceutical company, with development and...
- •Headquartered in the United States
- •Clinical development and corporate functions are U.S.-based
- •IRD patient populations exist in both U.S. and ex-U.S. markets
- •Future partnering and commercialization can extend internationally
Opus is focused on advancing its gene therapy pipeline for inherited retinal diseases while maintaining partnered and...
01
Advance gene therapy pipelinemedium-term
Clinical progress is the main path to value creation in rare ophthalmic diseases.
02
Partner non-core assetsshort-term
Collaborations can reduce funding needs and keep programs moving without full internal commercialization.
03
Expand ophthalmology portfoliomedium-term
Additional assets can diversify scientific risk and broaden the addressable market.
04
Monetize partnered productsshort-term
Royalties and milestones can provide non-dilutive support while pipeline assets mature.
Opus faces the typical risks of a clinical-stage biotech company: uncertain clinical outcomes, regulatory approval...
Manufacturing and scale-up risk
Gene therapies require specialized production capacity and quality control that can constrain trial execution and launch readiness.
- Scope
- AAV-based programs
- Materiality
- high
Intellectual property protection risk
The business depends on patents, licenses, and trademarks to protect product candidates and partner value.
- Scope
- U.S. and foreign IP rights
- Materiality
- high
Collaborator dependence
Milestones, reimbursements, and commercialization may depend on third parties that can change priorities or funding.
- Scope
- license and collaboration agreements
- Materiality
- medium
Financing and dilution risk
As a clinical-stage company, ongoing development requires external capital before product revenue is established.
- Scope
- equity, debt, and alternative financings
- Materiality
- high
License and collaboration revenue recognition
license agreements, Viatris-related revenue
Fair value of warrant and derivative liabilities
reported net loss volatility
Acquisition accounting and contingent consideration
balance sheet and future earnings
R&D expense estimation
research and development expense
: 29.4.2026